Atypical Antipsychotic

Hallucinations

Parkinson Disease

<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-11"></a><h1>11 DESCRIPTION</h1>NUPLAZID contains pimavanserin, an atypical antipsychotic, which is present as pimavanserin tartrate salt with the chemical name, urea, N-[(4-fluorophenyl)methyl]-N-(1-methyl-4-piperidinyl)-N'-[[4-(2-methylpropoxy)phenyl]methyl]-,(2R,3R)-2,3-dihydroxybutanedioate (2:1). Pimavanserin tartrate is freely soluble in water. Its molecular formula is (C25H34FN3O2)2∙C4H6O6 and its molecular weight is 1005.20 (tartrate salt). The chemical structure is:<div class="Figure"><img alt="Chemical Structure" src="nuplazid-01.jpg"/></div>The molecular formula of pimavanserin free base is C25H34FN3O2 and its molecular weight is 427.55.NUPLAZID capsules are intended for oral administration only. Each capsule contains 40 mg of pimavanserin tartrate, which is equivalent to 34 mg of pimavanserin free base. Inactive ingredients include magnesium stearate and microcrystalline cellulose. Additionally, the following inactive ingredients are present as components of the capsule shell: black iron oxide, FD&amp;C blue #1, hypromellose, titanium dioxide, and yellow iron oxide.NUPLAZID tablets are intended for oral administration only. Each round, orange, immediate-release, film coated tablet contains 11.8 mg of pimavanserin tartrate, which is equivalent to 10 mg pimavanserin free base. Inactive ingredients include magnesium stearate, pregelatinized starch, and silicified microcrystalline cellulose. Additionally, the following inactive ingredients are present as components of the film coat: polyethylene glycol, polyvinyl alcohol, red iron oxide, talc, titanium dioxide, and yellow iron oxide.</section>

NUPLAZID

pimavanserin

Nuplazid

pimavanserin 10 MG Oral Tablet

pimavanserin 10 MG Oral Tablet [Nuplazid]

pimavanserin 34 MG Oral Capsule

pimavanserin 34 MG Oral Capsule [Nuplazid]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Prescribing Information 

Submit MSL Request 

Pharmacy List 

Reimbursement Information 

Formulary Information 

Coding Guide 

Online Sample Form 

Coverage Authorization Request 

Coverage Authorization Appeals 

Letter of Medical Necessity 

Nuplazid Treatment & Service Request Form

Nuplazid Treatment & Service Request Form - Online 

Enroll in Patient Savings Program 

Other HCP Resources 

About Nuplazid 

Patient Stories 

FAQs: PD-Related Hallucinations & Delusions Fact Sheet 

Acadia Connect Support Program 

Patient Resources 

Instructions For Use: PD-Related Hallucinations & Delusions Fact Sheet 

Patient Brochure 

Doctor Discussion Guide 

Nuplazid Fact Sheet 

Nuplazid Fact Sheet - Spanish

PD-Related Hallucinations & Delusions Fact Sheet 

PD-Related Hallucinations & Delusions Fact Sheet - Spanish 